Dual inhibition: Combining epidermal growth factor-targeted therapies in non-small-cell lung cancer

Clinical Lung Cancer

Volumn 8, Issue 7, 2007, Pages 420-424

  Ho, Cheryl ^a,b   Davies, Angela ^a   Mack, Philip ^a   Gandara, David ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

Monoclonal antibodies; Stable disease; Tyrosine kinase inhibitors

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; PLACEBO;

ANOREXIA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEHYDRATION; DIZZINESS; DRUG DOSE ESCALATION; DRUG MECHANISM; DRUG POTENTIATION; FATIGUE; HEADACHE; HEARING IMPAIRMENT; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; INTERSTITIAL LUNG DISEASE; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; NAUSEA; PROTEINURIA; RASH; REVIEW; TREATMENT RESPONSE;

EID: 34547818723     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2007.n.025     Document Type: Review

References (40)

1. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000; 19:6550-6565.
2. Scagliotti GV, Selvaggi G, Novello S, et al. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004; 10:4227s-4232s.
3. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003; 21:3798-3807.
4. Meert AP, Martin B, Delmotte P, et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 2002; 20:975-981.
5. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-132.
6. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004; 22:785-794.
7. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004; 22:777-784.
8. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005; 23:5892-5899.
9. Gatzemeier U, Pluzanska A, Szczesna A, et al. Results of a phase III trial of erlotinib (OSI-774) combined with cisplatin and gemcitabine (GC) chemotherapy in advanced non-small cell lung cancer. J Clin Oncol 2004; 23(17 suppl):617 (Abstract #7010).
10. Gumerlock PH, Pryde BJ, Kimura T, et al. Enhanced cytotoxicity of docetaxel → OSI-774 combination in non-small cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol 2003; 22:662 (Abstract #2661).
11. Piperdi B, Ling Y-H, Kroog G, et al. Schedule-dependent interaction between epidermal growth factor inhibitors (EGFRI) and G2/M blocking chemotherapeutic agents (G2/MB) on human NSCLC cell lines in vitro. J Clin Oncol 2004; 23:620 (Abstract #7028).
12. Davies AM, Lara PN, Lau DH, et al. Intermittent erlotinib in combination with docetaxel (DOC): phase I schedules designed to achieve pharmacodynamic separation. J Clin Oncol 2005; 23(16 suppl):630s (Abstract #7038).
13. Davies AM, Ho C, Lara PN Jr, et al. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer 2006; 7:385-388.
14. Kris MG, Sandler A, Miller V, et al. Cigarette smoking history predicts sensitivity to erlotinib: results of a phase II trial in patients with bronchioloalveolar carcinoma (BAC). J Clin Oncol 2004; 23:628 (Abstract #7062).
15. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
16. Miller VA, Kris MG, Shah N, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004; 22:1103-1109.
17. Miller VA, Patel J, Shah N, et al. The epidermal growth factor receptor tyrosine kinase inhibitor erlotinib (OSI-774) shows promising activity in patients with bronchioloalveolar cell carcinoma (BAC): preliminary results of a phase II trial. Proc Am Soc Clin Oncol 2003; 22:619 (Abstract #2491).
18. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-1500.
19. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group study. J Clin Oncol 2005; 23:6838-6845.
20. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005; 353:133-144.
21. Balak MN, Gong Y, Riely GJ, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res 2006; 12:6494-6501.
22. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006; 24:5034-5042.
23. Eberhard DA, Johnson BE, Amler LC, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005; 23:5900-5909.
24. Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Medicine 2005; 2:e17.
25. Kokubo Y, Gemma A, Noro R, et al. Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA). Br J Cancer 2005; 92:1711-1719.
26. Lilenbaum R, Bonomi P, Ansari R, et al. A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC): final results. J Clin Oncol 2005; 23(16 suppl):629s (Abstract #7036).
27. Kelly K, Hanna N, Rosenberg A, et al. A multi-centered phase I/II study of cetuximab in combination with paclitaxel and carboplatin in untreated patients with stage IV non-small cell lung cancer. Proc Am Soc Clin Oncol 2003; 22:644 (Abstract #2592).
28. ClinicalTrials.gov Web site. Study of taxane/carboplatin +/- cetuximab as first-line treatment for patients with advanced/metastatic non-small cell lung cancer. Available at: http://clinicaltrials.gov/ct/show/NCT00112294?order=1. Accessed May 30, 2007.
29. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345.
30. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23:1803-1810.
31. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 2005; 6:279-286.
32. Sok JC, Coppelli FM, Thomas SM, et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin Cancer Res 2006; 12:5064-5073.
33. Huang S, Armstrong EA, Benavente S, et al. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004; 64:5355-5362.
34. Matar P, Rojo F, Cassia R, et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 2004; 10:6487-6501.
35. Minna JD, Peyton MJ, Gazdar AF. Gefitinib versus cetuximab in lung cancer: round one. J Natl Cancer Inst 2005; 97:1168-1169.
36. Mukohara T, Engelman JA, Hanna NH, et al. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 2005; 97:1185-1194.
37. Kimura H, Sakai K, Arao T, et al. Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild- and mutant-EGFR. Presented at: the 97th Annual Meeting of the American Associated of Cancer Research; April 1-5, 2006; Washington, DC.
38. Baselga J, Schoffski P, Rojo F, et al. A phase I pharmacokinetic (PK) and molecular pharmacodynamic (PD) study of the combination of two anti-EGFR therapies, the monoclonal antibody (MAb) cetuximab (C) and the tyrosine kinase inhibitor (TKI) gefitinib (G), in patients (pts) with advanced colorectal (CRC), head and neck (HNC) and non-small cell lung cancer (NSCLC). J Clin Oncol 2006; 24(18 suppl):122s (Abstract #3006).
39. Naret CL, Ramalingam S, Beattie L, et al. Total blockade of the epidermal growth factor receptor with the combination of cetuximab and gefitinib: a phase I study for patients with recurrent non-small cell lung cancer (NSCLC). J Clin Oncol 2006; 24(18 suppl):670s (Abstract #17045).
40. Preston GG, Calvo E, Papadopoulos K, et al. Multi-targeted inhibition of the epidermal growth factor (EGFR) and vascular endothelial growth factor receptor (VEGFR) pathways: a phase I study of cetuximab (C), erlotinib (E), and bevacizumab (B) in patients with solid tumors. J Clin Oncol 2006; 24(18 suppl):122s (Abstract #3005).